All Resources

Access to Medicine • August 21, 2023

IMC Response to the PMPRB’s 2023 Interim Guidance Consultation

Learn more | View

Access to Medicine • August 21, 2023

pCPA Temporary Access Process: Innovative Medicines Industry Consultation Response

Learn more | View

June 08, 2023

Submission for the parliamentary consultations on Bill 15—An Act to Make the Health and Social Services more effective

Learn more | View

May 04, 2023

Submission to Health Canada regarding the proposed plan for the future use and availability of the drug establishment licence (DEL) and good manufacturing practices (GMP)

Learn more | View

Access to Medicine • February 15, 2023

Alberta Budget Submission 2023

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Learn more | View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View

Ethics • January 01, 2022

2022 Code of Ethical Practices

Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to…

Learn more | View

Drugs for Rare Diseases (DRD) • September 15, 2021

Addendum to IMC Submission on Drugs for Rare Diseases

Learn more | View

Access to Medicine • August 06, 2021

2022 Federal Pre-Budget Consultation

Learn more | View